Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Finance
  • Published:

Venture capital with a European twist

Nature Biotechnology volume 17, pages 23–24 (1999)Cite this article

Abstract

Cultural factors suggest that European venture capitalists will follow a different model than their US counterparts in selecting companies to fund.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. managing director BankInvest Biomedical Development, Toldbodgade 33, 1022, Copenhagen K, P.O. Box 9011, Denmark

    Florian Schönharting

  2. analyst at BankInvest Biomedical Development, Toldbodgade 33, 1022, Copenhagen K, P.O. Box 9011, Denmark

    Thomas Tscherning

  3. science writer in, Copenhagen

    Lone Frank

Authors
  1. Lone Frank
    View author publications

    Search author on:PubMed Google Scholar

  2. Thomas Tscherning
    View author publications

    Search author on:PubMed Google Scholar

  3. Florian Schönharting
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frank, L., Tscherning, T. & Schönharting, F. Venture capital with a European twist. Nat Biotechnol 17 (Suppl 3), 23–24 (1999). https://doi.org/10.1038/9098

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/9098

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing